Table 2:
Final P2Y12 receptor antagonist dosing regimen and associated major thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the PED
| No. of Patients (%) | Major Complications (%) | Outside Target P2Y12 Receptor-Inhibition Range (PRU 60–240)a (%) | |
|---|---|---|---|
| All patients | 44 (100) | 5 (11.4) | 4 (80) |
| Clopidogrel | 31 (71) | 3 (9.7) | 3 (100) |
| 150 mg daily | 3 (9.7) | 1 Infarction, 1 ICH (66.7) | 2 (100) |
| 75 mg daily | 15 (48.3) | 0 | |
| 75 mg QOD | 2 (6.5) | 0 | |
| 75 mg Q3D | 3 (9.7) | 0 | |
| 75 mg QMF | 5 (16.1) | 0 | |
| 75 mg Q4D | 2 (6.5) | 1 ICH (50)b | 1 (100) |
| 75 mg Q5D | 1 (3.2) | 0 | |
| Prasugrel | 12 (27) | 2 (16.7) | 1 (50) |
| 10 mg daily | 6 (50) | 1 ICH (16.7) | 1 (100) |
| 5 mg daily | 5 (41.7) | 1 ICH (20) | 0 |
| 5 mg QOD | 1 (8.3) | 0 | |
| Ticagrelor | 1 (2) | 0 | |
| 90 mg BID | 1 (100) |
Note:—QOD indicates every other day; Q3D, every third day; QMF, every Monday and Friday; Q4D, every fourth day; Q5D, every fifth day; BID, twice a day.
a
Shortly before or at the time of a major complication.
b
Recurrent ICH with subdural extension contralateral to the PED on postoperative day 50 in a patient with postmortem examination–proven amyloid angiopathy at the site of ICH (PRU 58 at the time of ICH, Fig 2).